Message Board

  • First name*
  • Last name*
  • Email*
  • Mobile*
  • Company/Organization name*
  • Company/Organization type*
  • Department*
  • Job title*
  • How did you hear about us?*
  • Product*
  • Your message

Yaocheng Health Science&Technology, a pioneer in the fusion of life sciences and AI computer science, is committed to building AuroraPrime, a globally leading AI-enabled integrated clinical research platform. Utilizing cutting-edge AI models, cloud computing, and big data technology, it fully supports clinical trials and real-world studies, accelerating innovation and enhancing market competitiveness. AuroraPrime's integrated platform features an open and flexible technical architecture, seamlessly integrating data and documents throughout the clinical research process, ensuring data quality and compliance. Utilizing advanced AI technology from both domestic and international sources, we provide intelligent support for the entire process of global multicenter clinical research. This enhances clinical operational efficiency, achieves process automation and intelligent decision-making, empowers the acceleration of pharmaceutical products to market, and establishes competitive barriers for enterprises.

Management Team

Sharon Chen


Pengcheng Xu

Chairman & CTO

Gavin Zhang


Bogong Zhu


Alice Hsu

SVP of Clinical Technology Service & Consulting

Scientific Advisor

Névine Zariffa

Ruyi He

Kun He

Brand story

In 2020, a group of senior technology and product experts from Google and Verily China decided to start a business and delve into the intelligent digitalization of life science clinical research. With the goal of building a SaaS platform for life science and consumer health fields through world-leading computer technology, Yaocheng was officially established in August 2020. With the vision of "Use technology to advance innovation in life science and consumer health. Faster, more accessible and evidence-based," the Yaocheng team quickly grew and attracted many technology talents from leading global IT companies and senior industry experts from the life sciences field. With the gradual launch of AuroraPrime's innovative products, more and more leading life science innovation and development companies, as well as ecosystem partners, choose AuroraPrime, collaborate in multiple ways, and jointly explore the future of intelligent digitalization in clinical research.


Rapid Development & Investor Trusted


Yaocheng was officially established in Shanghai, China.


Completed seed round financing


Opened office in Beijing.


Officially launched AuroraPrime 1.0


Completed Series A financing of hundreds of millions of RMB.


Officially launched AuroraPrime 2.0


2022 - Yaocheng's HQ office officially relocated to SK Tower in Shanghai.


Completed Series A+ financing of tens of millions of USD.


AuroraPrime completed integration with AGI platform

Part of Our Investment Partners

Hankang Capital

Lightspeed China Partners

B Capital Group

Artificial Intelligence Industry Investment Fund

Primavera Capital Group

Legend Star

Improve the efficiency of clinical research and development and
bring innovative products to market faster.


Sharon Chen | CEO

Ms. Chen Xiao, Co-Founder and CEO of Shanghai Yaocheng Health Technology, brings over 15 years of product development experience from Google. She has been involved in the development of multiple core platforms at Google, accumulating extensive technical expertise and receiving prestigious awards, including the 'Founders' Award' and the unique 'Great Manager Award' in the Asia-Pacific region.

Her career began at Google's U.S. headquarters as a Software Engineer, and she later rose to the position of Head of Google Shanghai Research Institute. Subsequently, she became the General Manager of Verily China, a subsidiary of Google focused on the life sciences sector. Before joining Google, Ms. Chen worked in software technology development and management roles at companies such as Experian and Brocade in the United States. She holds a bachelor's degree in Control Science and Engineering from Shanghai Jiao Tong University and a master's degree in Computer Science from Texas A&M University.

Ms. Chen's interdisciplinary expertise, at the intersection of artificial intelligence, technology R&D, and life sciences, positions her as an exceptional leader, contributing significant value to her company and the life sciences industry.

Pengcheng Xu | Chairman & CTO

Mr.Xu Pengcheng, a key technical expert at Verily China, founded Shanghai Yaocheng Health Science & Technology Co., Ltd. in 2020 and currently serves as Chairman and CTO, responsible for technical research and development, as well as internal operations and management.

Prior to joining Yaocheng, Pengcheng worked at Google for 12 years and was the first local engineer at Google China. After leaving Google, he served as the Chief System Architect at Verily China, an entrepreneurial company focused on life sciences under the umbrella of Google's parent company.

Mr.Xu Pengcheng graduated from the Department of Computer Science and Technology at Peking University with a bachelor's degree.

Gavin Zhang | CBO

As the co-founder, Gavin Zhang is currently the CBO of Shanghai Yaocheng Health Science & Techonlogy Co.,Ltd. responsible for the overall sales, marketing and business strategy.

Before joining Yaocheng, Gavin worked for Medidata as the head of channel sales in Asia Pacific region. He also worked in sales, channel and R&D management positions in Microsoft, Oracle, EMC, NetApp and other companies in the last 20 plus years.

Gavin graduated from Tianjin University of Finance and economics with a bachelor's degree in economics and a master's degree in Business Administration from Peking University and University of Leuven Ghent.

Bogong Zhu | CPO

Mr. Zhu Bogong, Co-Founder and Chief Product Officer (CPO) at Shanghai Yaocheng Health Technology, is a visionary leader renowned for his exceptional prowess in AI and a remarkable integration of technology and life sciences. In 2020, he co-founded the company, spearheading product development and innovation. With over 13 years of expertise garnered at Google, his profound technological acumen shines, particularly in Ads and Cloud AI projects. He further refined his skills as a technology executive at Verily China, a Google subsidiary dedicated to life sciences. Holding a bachelor's degree in Software Engineering from East China Normal University and an MBA from Shanghai Jiao Tong University, Mr. Zhu's cross-disciplinary mastery sets him apart in the convergence of technology and life sciences. He provides profound AI insights and exemplifies strong leadership, making substantial contributions to both the company and the life science industry at large.

Alice Hsu | SVP of Clinical Technology Service & Consulting

Alice Hsu is currently the SVP of Clinical Technology Services & Consulting at Shanghai Yaocheng Health Science & Technology Co., Ltd. Her responsibilities includes lead of Clinical Technology team, provide clinical trial operations knowledge as well system development and strategies support to the organization. To therefore bring in efficiency and quality services for clients in the use of Yaocheng’s integrated system platform.

Prior to joining Yaocheng Healthcare Technology, Alice has over 15 years of experiences in the CRO industry with positions held in IQVIA, Covance, WuXi Clinical and PPD respectively where she was based in Taipei, Singapore and Shanghai. Her main scope of work and responsibilities over the years included from technical delivery of projects to leadership roles in clinical operation and project management departments.

Alice graduated from Johns Hopkins University Bloomberg School of Public Health and University of Illinois, Urbana Champaign with MHS and M.S. majored in Nutritional Sciences and Immunophysiology.

Névine Zariffa

Névine is a highly accomplished thought leader in the fields of biostatistics and data science with extensive experience across all phases of drug development. Névine had a 25-year career in senior roles at GlaxoSmithKline and AstraZeneca where she also led the Enterprise Data & Analytics initiative. She has been a key contributor to development strategies for over 200 drug projects across oncology, cardiovascular, metabolic, respiratory, inflammation, and renal diseases. She has been a reviewer for The Lancet and has over 30 peer reviewed publications to her name. She is a strategic consultant to several organisations including scientific data consortia such as ctDNA. She advised FDA (Office of the Principal Deputy Commissioner) on the application of real-world evidence to COVID19. She serves on the Scientific Advisory Board of ANOVA, ZS Associates, and Intelligencia. She was a Board member of CDISC for 6 years.

Ruyi He

Dr. Ruyi He is the Chief Medical Officer of RemeGen CO., Ltd. and Chief Scientist of SDIC Fund Management CO., LTD and former Chief Scientist at the Center for Drug Evaluation at the National Medical Products Administration (NMPA). Dr. He joined NMPA in July 2016, after having worked at the US Food and Drug Administration (FDA) for more than 17 years. Dr. He joined the US Center for Drug Evaluation and Research (CDER) at the US FDA in 1999 as a Medical Officer in the Division of Gastrointestinal and Coagulation Drug Products and later served as the Acting Deputy Director in the division for years. Dr. He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. and received his clinical and research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. He is a licensed, board-certified physician in Internal Medicine in the USA.

Kun He

Kun He, Ph.D., is the Chief Statistician of R&G US Inc. since January 2019, and formerly worked at the CDER/FDA for 20 years, most recently serving as Associate Division Director of the Division of Biometrics V, supporting the Office of Hematology and Oncology Products. During his FDA tenure, he reviewed thousands of INDs, including I-SPY2, Lung-Map, and GBM Agile, and hundreds of NDA/BLAs, including the initial approvals of Keytruda and Opdivo. Prior to joining the FDA in April 1999, he served on the faculties of the University of Kansas and the University of Minnesota. Dr. He received a Ph.D. in Statistics from Cornell University.